1. Primus Pharma halts production, marketing of Limbrel in response to FDA safety concerns
Scottsdale, Ariz.-based Primus Pharmaceuticals took its osteoarthritis treatment Limbrel off the market at the FDA’s request.
2. PharMEDium recalls 25k drug units due to sterility issues: 4 things to know
PharMEDium is recalling 55 lots of various drug products due to a lack of sterility assurance.
3. Allergan to cut more than 1k jobs: 3 things to know
Allergan will eliminate more than 1,000 positions in anticipation of generic competition surrounding its popular dry-eye drug Restasis.
4. First gene therapy drug priced lower than expected at $850k
Spark Therapeutics’ Luxturna, the first gene therapy to gain FDA approval for the treatment of a rare, inherited retinal disease that can lead to blindness, will cost patients $850,000 for a one-time treatment, or $425,000 per eye.
5. Microsoft partners with Adaptive Biotechnologies to ‘decode’ immune systems with AI
Microsoft has joined forces with Adaptive Biotechnologies, a Seattle-based biotech company, to map the human immune system, according to a Jan. 4 Microsoft blog post by Peter Lee, PhD, the company’s corporate vice president of artificial intelligence and research.
6. FDA issues recall of J&J’s heart device over faulty valve
The FDA issued a Class I recall Jan. 2 for a heart device manufactured and distributed by a unit of Johnson & Johnson — citing a faulty valve.
More articles on supply chain:
Celgene to acquire Impact Biomedicines for up to $7B
AdvaMed TV ads call on Congress to end device tax: 4 things to know
FDA OKs expanded use of Amgen’s bone drug: 4 things to know
